Last mentioned: Feb 27, 2026
Anticipated Milestones
Expected expansion of WRBY's insurance network and SEER's multi-omics software updates.
Market Analysis
Analysts highlight the shift toward integrated health platforms in both consumer and clinical sectors.
Q4 Earnings Calls
Warby Parker and Seer, Inc. both report year-end results, outlining 2026 growth strategies.
Q4 2025 Earnings Call
Company reports strong year-end results and outlines 2026 growth strategy.
Precision-Vision Expansion
Rollout of advanced eye exam technology to 75% of existing stores.
200th Store Milestone
Warby Parker opens its 200th physical retail location in the U.S.
Virtual Try-On 2.0
Launch of enhanced AI-driven virtual try-on features for mobile users.
Warby Parker reported strong Q4 2025 results, highlighting the success of its integrated bricks-and-clicks model and expansion into comprehensive eye care. The company continues to outpace the broader optical industry through strategic store openings and increased penetration in the contact lens market.
Warby Parker and Seer, Inc. both reported Q4 2025 results on February 26, 2026, revealing contrasting strategies for growth in the retail and life sciences sectors. While Warby Parker is leveraging physical store expansion to drive vision care services, Seer is navigating the complex commercialization of its proteomics platform.
Seer, Inc. and Warby Parker Inc. reported Q4 2025 results, highlighting a pivotal shift toward high-scale proteomics and clinical healthcare services respectively. While Seer focuses on deep-tech life sciences tools, Warby Parker is increasingly positioning itself as a primary eye care provider.
Warby Parker and Seer, Inc. reported Q4 2025 results, highlighting a pivot toward integrated health platforms and advanced diagnostic capabilities. While Warby Parker expands its telehealth and physical eye care ecosystem, Seer is accelerating the commercialization of its proteomics technology to redefine precision medicine.